Poster Session 1: Leukemia
Poster Abstracts
Longhorn Hall E (Exhibit Level 1) (Gaylord Texan)
Central Nervous System Leukemia in Acute Myeloid Leukemia
Mohamad Altriki, MD, Mayo Clinic Arizona;
Meng-Ru Cheng, Mayo Clinic Arizona;
Veena Fauble, MD, Mayo Clinic Arizona;
Nandita Khera, MD, Mayo Clinic Arizona;
Jose Leis, MD, PhD, Mayo Clinic Arizona;
Ruben A. Mesa, MD, FACP, Mayo Clinic Arizona;
Pierre Noel, MD, Mayo Clinic Arizona;
James L. Slack, MD, Mayo Clinic Arizona;
Raoul Tibes, MD, PhD, Mayo Clinic Arizona;
Lisa Ostrosky Sproat, MD, MSW, Mayo Clinic Arizona
Allogeneic Stem Cell Transplantation in High Risk ALL Patients: Influence of ALL Subtypes
Renate Arnold, MD, Charité - Universitätsmedizin Berlin;
Theis Terwey, MD, Charité - Universitätsmedizin Berlin;
Lam Vuong, PhD, Charité - Universitätsmedizin Berlin;
Benjamin Ostendorf, Charitè Universitiy Medicine Berlin;
Olaf Penack, Charitè University Medicine Berlin;
Gero Massenkeil, Klinikum Gütersloh;
Philipp Hemmati, MD, Charité - Universitätsmedizin Berlin
Phase I Trial of Maintenance Sorafenib after Allogeneic HSCT for Patients with FLT3-ITD AML
Yi-Bin Chen, MD, Massachusetts General Hospital;
Shuli Li, Dana-Farber Cancer Institute;
Andrew A. Lane, Dana-Farber Cancer Institute;
Candice Del Rio, RN, Massachusetts General Hospital;
Christine Connolly, Massachusetts General Hospital;
Karen K. Ballen, MD, Massachusetts General Hospital;
Corey S. Cutler, MD, Dana-Farber Cancer Institute;
Bimalangshu R Dey, MD, PhD, Massachusetts General Hospital;
Amir T. Fathi, MD, Massachusetts General Hospital;
Vincent T. Ho, MD, Dana Farber Cancer Institute;
Amy Joyce, Dana-Farber Cancer Institute;
Steven L. McAfee, MD, Massachusetts General Hospital;
Thomas R. Spitzer, MD, Massachusetts General Hospital;
Mark Levis, Johns Hopkins University;
Robert J. Soiffer, MD, Dana-Farber Cancer Institute
Clofarabine ± Fludarabine with IV Busulfan and Allogeneic Stem Cell Transplantation for Advanced Myeloid Leukemia (ML) and MDS
Diem Chu, MS, PA-C, UT MD Anderson Cancer Center;
Ben C. Valdez, PhD, UT MD Anderson Cancer Center;
Patricia S Fox, MS, UT MD Anderson Cancer Center;
Peter Thall, PhD, UT MD Anderson Cancer Center;
Laura Worth, MD, PhD, UT MD Anderson Cancer Center;
Uday R. Popat, MD, The University of Texas MD Anderson Cancer Center;
Roy B. Jones, MD, PhD, UT M.D. Anderson Cancer Center;
Elizabeth J. Shpall, MD, UT MD Anderson Cancer Center;
Chitra Hosing, MD, The University of Texas MD Anderson Cancer Center;
Amin M. Alousi, MD, UT MD Anderson Cancer Center;
Gabriela Rondon, MD, UT M.D. Anderson Cancer Center;
Partow Kebriaei, MD, UT M.D. Anderson Cancer Center;
Richard E. Champlin, MD, UT MD Anderson Cancer Center;
Borje S. Andersson, MD, PhD, UT MD Anderson Cancer Center
Allogenic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia with or without Consolidation Chemotherapy
Ardeshir Ghavamzadeh, M.D., Tehran University of Medical Sciences;
Kamran Alimoghaddam, M.D., Tehran University of Medical Sciences;
Mohammad Jahani, Tehran University of Medical Sciences;
Seyyed Asadollah Mousavi, Tehran University of Medical Sciences;
Babak Bahar, Tehran University of Medical Sciences;
Mohammad Vaezi, Hematology,Oncology and Stem cell Transplantation Research Center;
Leila Sharifi Aliabadi, Tehran University of Medical Sciences;
Arash Jalali, Tehran University of Medical Sciences
The Role for Induction Chemotherapy and Allogeneic Stem Cell Transplant in Patients with Chronic Myelomonocytic Leukemia That Have Undergone Leukemic Transformation: A Single Center Experience
Wilson I Gonsalves, MD, Mayo Clinic;
Naseema Gangat, MD, Mayo Clinic;
Vinay Gupta, MD, Mayo Clinic;
Aref Al-Kali, MD, Mayo Clinic;
William Hogan, MBBCh, Mayo Clinic;
Shahrukh Hashmi, MD, Mayo Clinic;
Mark R Litzow, MD, Mayo Clinic;
Mrinal Patnaik, MD, Mayo Clinic
Long-Term Outcome of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia Beyond First Complete Remission – a Single Center Experience
Philipp Hemmati, MD, Charité - Universitätsmedizin Berlin;
Theis Terwey, MD, Charité - Universitätsmedizin Berlin;
Lam Vuong, PhD, Charité - Universitätsmedizin Berlin;
Il-Kang Na, MD, Charité - Universitätsmedizin Berlin;
Philipp le Coutre, MD, Charité - Universitätsmedizin Berlin;
Bernd Dörken, MD, Charité - Universitätsmedizin Berlin;
Renate Arnold, MD, Charité - Universitätsmedizin Berlin
Cord Blood Transplantation for Primary Refractory Acute Myeloid Leukemia
Kosei Kageyama, Toranomon Hospital;
Hisashi Yamamoto, MD, Toranomon Hospital;
Daisuke Kaji, Toranomon Hospital;
Hikari Ota, MD, Toranomon Hospital;
Kazuya Ishiwata, MD, Toranomon Hospital;
Masanori Tsuji, MD, Toranomon Hospital;
Go Yamamoto, MD, PhD, Toranomon Hospital;
Yuki Asano-Mori, MD, PhD, Toranomon Hospital;
Naoyuki Uchida, MD, Toranomon Hospital;
Koji Izutsu, MD, PhD, Toranomon Hospital;
Shuichi Taniguchi, MD, PhD, Toranomon Hospital
Preliminary Data from a Multi-Center Study of Clofarabine / Busulfan Conditioning for Acute Myeloid Leukemia Not in Remission at Allogeneic Transplantation
John Magenau, M.D., University of Michigan;
Peter Westervelt, MD, PhD, Washington University School of Medicine;
Joseph P McGuirk, DO, University of Kansas Med Ctr MS 5003;
Samer K Khaled, MBBCh, MD, City Of Hope;
Pamela S. Becker, Fred Hutchinson Cancer Research Center;
Madan H. Jagasia, MD, MBBS, MS, Vanderbilt University Medical Center;
Scott Rowley, MD, Hackensack University Medical Center;
Dennis Kim, Princess Margaret Hospital, University of Toronto;
Noelle V. Frey, Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania;
Hari Parameswaran, MD, Medical College of Wisconsin;
Stefanie Lieland, University of Michigan;
Thomas Braun, PhD, University of Michigan;
Tal Schechter-Finkelstein, MD, Hospital for Sick Children;
Brian Parkin, MD, University of Michigan;
Andrew C. Harris, M.D., University of Michigan;
Bart Lee Scott, MD, Fred Hutchinson Cancer Research Center;
John F. DiPersio, MD, PhD, Washington University School of Medicine;
Stephen J. Forman, MD, City of Hope National Medical Center;
Shin Mineishi, MD, University of Alabama at Birmingham, Birmingham, AL
Induction of a CD8+ T Cell Response to Tumor Antigens Is Associated with Improved Survival in Patients Transplanted for Acute Myeloid Leukemia
Sandeep Nagra, Queen Elizabeth Hospital;
Oliver Charles Goodyear, University of Birmingham;
Josephine Khan, University of Birmingham;
Nadira Yasmin Jilani, Queen Elizabeth Hospital;
Paul Ferguson, Queen Elizabeth Hospital;
Nigel Russell, Nottingham City Hospital;
Mike Dennis, The Christie Hospital;
Paresh Vyas, University of Oxford;
Shamyla Siddique, Queen Elizabeth Hospital;
Charles Craddock, Queen Elizabeth Hospital
Allogeneic (Allo) Stem Cell Transplantation (SCT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1) with a Reduced Intensity Conditioning (RIC) of Fludarabine (Flu), 2 Day Busulfan (Bu2) and Horse ATG (hATG): The UMass Experience
Rajneesh Nath, MD, UMass Memorial Medical Center;
Jan Cerny, MD, PhD, University of Massachusetts;
Muthalagu Ramanathan, MD, UMASS Memorial University Campus;
Glen Raffel, MD, PhD, UMass Medical Center;
Mridula George, MD, UMass Medical Center;
Zeina Al-Mansour, MD, UMass Memorial Medical Center;
Laura Petrillo-Deluca, PAC, UMass Memorial Medical Center;
Tzafra Martin, PAC, UMass Memorial Medical Center;
Zankar Desai, University of Massachusetts Medical Center;
Jayde Bednarik, PharmD, UMass Memorial Medical Center;
Aimee Kroll-Desrosiers, MS, University of Massachussets;
Alan Rosmarin, MD, UMass Memorial
Extended Dose-Total Body Irradiation (18Gy) Followed By an Allogeneic Cell Transplantation for the Treatment of Refractory Acute Myeloid Leukemia: Early Results
Mitchell Sabloff, MSc., MDCM, The Ottawa Hospital Blood & Marrow Transplant Program;
Sultan Altouri, MD, The Ottawa Hospital Blood & Marrow Transplant Program;
Harold Atkins, MD, The Ottawa Hospital Blood & Marrow Transplant Program;
David S Allan, MD, The Ottawa Hospital Blood & Marrow Transplant Program;
Jason Tay, MD, Msc., The University of Ottawa;
Mai Le, The Ottawa Hospital;
Linda Hamelin, APN, The Ottawa Hospital Blood & Marrow Transplant Program;
Rajiv Samant, MD, The University of Ottawa;
Dawn Sheppard, BSc, MSc, MD, The Ottawa Hospital Blood & Marrow Transplant Program;
Lothar B Huebsch, MD, The Ottawa Hospital Blood & Marrow Transplant Program;
Tim Ramsay, MSc, PhD, The University of Ottawa;
Christopher N. Bredeson, MD, MSc, The Ottawa Hospital Blood & Marrow Transplant Program
Synergistic Cytotoxicity of the Multikinase Inhibitor Sorafenib with the DNA Alkylating Agent Busulfan, and Nucleoside Analogs in Human FLT3-ITD-Positive Acute Myeloid Leukemia Cell Lines
Guiyun Song, PhD, UT MD Anderson Cancer Center;
Ben C. Valdez, PhD, UT MD Anderson Cancer Center;
Yang Li, MS, UT MD Anderson Cancer Center;
Yan Liu, UT MD Anderson Cancer Center;
Richard E. Champlin, MD, UT MD Anderson Cancer Center;
Borje S. Andersson, MD, PhD, UT MD Anderson Cancer Center
